letrozole has been researched along with Osteoporosis, Postmenopausal in 18 studies
Osteoporosis, Postmenopausal: Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 551 postmenopausal women with breast cancer who completed tamoxifen treatment and were undergoing daily letrozole treatment were randomized to either upfront (274 patients) or delayed (277 patients) ZA at a dose of 4 mg intravenously every 6 months." | 9.20 | 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. ( Dakhil, SR; Hines, SL; Kearns, AE; Lafky, JM; Liu, H; Loprinzi, CL; Perez, EA; Puttabasavaiah, S; Sloan, JA; Wagner-Johnston, ND, 2015) |
| "Letrozole is a proven and effective adjuvant therapy in postmenopausal women with hormone receptor-positive (HR(+)) early breast cancer (EBC)." | 9.16 | Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. ( Deleu, I; Frassoldati, A; Jerusalem, G; Llombart, A; Mebis, J; Miller, J; Neven, P; Paija, O; Schenk, N; Sleeboom, HP, 2012) |
| "The addition of ZOL to letrozole was safe and efficacious in maintaining LS BMD in postmenopausal patients with hormone receptor-positive breast cancer and who were receiving letrozole following 2." | 9.15 | The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial. ( Bernstein-Molho, R; Geffen, DB; Greenberg, J; Inbar, MJ; Pelles-Avraham, S; Safra, T; Sarid, D; Stemmer, SM; Stephansky, I, 2011) |
| "In this multicenter study, postmenopausal women with early hormone receptor-positive breast cancer receiving adjuvant letrozole were randomized to receive up-front or delayed-start zoledronic acid (ZA; 4 mg intravenously every 6 months) for 5 years." | 9.14 | Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. ( Bosserman, LD; Brufsky, AM; Caradonna, RR; Ericson, SG; Haley, BB; Jin, L; Jones, CM; Moore, HC; Perez, EA; Warsi, GM, 2009) |
| "The interim (12-month) results of two similarly designed, ongoing studies (the Zometa-Femara Adjuvant Synergy Trials [Z-FAST and ZO-FAST]) suggest that zoledronic acid (4 mg intravenously every 6 months) when initiated with adjuvant letrozole increases bone mineral density (BMD) of the lumbar spine (LS) in postmenopausal women with early-stage breast cancer compared with patients who receive zoledronic acid only when bone loss became clinically significant or a fragility fracture occurred." | 9.13 | Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. ( Brufsky, A; Bundred, N; Coleman, R; Ericson, S; Hadji, P; Jin, L; Lambert-Falls, R; Mena, R; Perez, EA; Schenk, N, 2008) |
| "Letrozole is safe and effective in postmenopausal women with estrogen receptor-positive early breast cancer, but long-term aromatase inhibitor use may cause bone loss and increase fracture risk." | 9.13 | Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. ( Bundred, NJ; Campbell, ID; Coleman, RE; Davidson, N; DeBoer, RH; Eidtmann, H; Miller, JC; Monnier, A; Neven, P; Schenk, NL; von Minckwitz, G, 2008) |
| "With 1 year of follow-up, results of the primary end point of the Zometa-Femara Adjuvant Synergy Trial (Z-FAST) indicate that upfront zoledronic acid therapy prevents bone loss in the LS in postmenopausal women receiving adjuvant letrozole for early-stage breast cancer." | 9.12 | Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. ( Beck, JT; Brufsky, A; Carroll, R; Harker, WG; Hohneker, J; Lacerna, L; Perez, EA; Petrone, S; Seidler, C; Tan-Chiu, E, 2007) |
| "Postmenopausal breast cancer (BC) patients receiving adjuvant aromatase inhibitor therapy are at risk of progressive bone loss and fractures." | 6.77 | Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. ( Argonza-Aviles, E; Beck, JT; Bosserman, L; Brufsky, AM; Ericson, SG; Harker, WG; Hohneker, J; Jin, L; Perez, EA; Seidler, C; Vogel, C; Warsi, G, 2012) |
| "Postmenopausal women with breast cancer (BC) are at increased risk for bone loss." | 6.74 | Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. ( Alberts, S; Dentchev, T; Hines, SL; Johnson, DB; Kahanic, S; Liu, H; Loprinzi, CL; Mazurczak, MA; Mincey, B; Nikcevich, DA; Perez, EA; Schaefer, PL; Sloan, JA, 2009) |
| "Women undergoing treatment for breast cancer often have a number of pre-existing risk factors for bone loss, including existing or induced postmenopausal status." | 6.43 | Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. ( Aapro, M, 2006) |
| "A total of 551 postmenopausal women with breast cancer who completed tamoxifen treatment and were undergoing daily letrozole treatment were randomized to either upfront (274 patients) or delayed (277 patients) ZA at a dose of 4 mg intravenously every 6 months." | 5.20 | 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. ( Dakhil, SR; Hines, SL; Kearns, AE; Lafky, JM; Liu, H; Loprinzi, CL; Perez, EA; Puttabasavaiah, S; Sloan, JA; Wagner-Johnston, ND, 2015) |
| "Letrozole is a proven and effective adjuvant therapy in postmenopausal women with hormone receptor-positive (HR(+)) early breast cancer (EBC)." | 5.16 | Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. ( Deleu, I; Frassoldati, A; Jerusalem, G; Llombart, A; Mebis, J; Miller, J; Neven, P; Paija, O; Schenk, N; Sleeboom, HP, 2012) |
| "The addition of ZOL to letrozole was safe and efficacious in maintaining LS BMD in postmenopausal patients with hormone receptor-positive breast cancer and who were receiving letrozole following 2." | 5.15 | The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial. ( Bernstein-Molho, R; Geffen, DB; Greenberg, J; Inbar, MJ; Pelles-Avraham, S; Safra, T; Sarid, D; Stemmer, SM; Stephansky, I, 2011) |
| "In this multicenter study, postmenopausal women with early hormone receptor-positive breast cancer receiving adjuvant letrozole were randomized to receive up-front or delayed-start zoledronic acid (ZA; 4 mg intravenously every 6 months) for 5 years." | 5.14 | Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. ( Bosserman, LD; Brufsky, AM; Caradonna, RR; Ericson, SG; Haley, BB; Jin, L; Jones, CM; Moore, HC; Perez, EA; Warsi, GM, 2009) |
| "The interim (12-month) results of two similarly designed, ongoing studies (the Zometa-Femara Adjuvant Synergy Trials [Z-FAST and ZO-FAST]) suggest that zoledronic acid (4 mg intravenously every 6 months) when initiated with adjuvant letrozole increases bone mineral density (BMD) of the lumbar spine (LS) in postmenopausal women with early-stage breast cancer compared with patients who receive zoledronic acid only when bone loss became clinically significant or a fragility fracture occurred." | 5.13 | Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. ( Brufsky, A; Bundred, N; Coleman, R; Ericson, S; Hadji, P; Jin, L; Lambert-Falls, R; Mena, R; Perez, EA; Schenk, N, 2008) |
| "Letrozole is safe and effective in postmenopausal women with estrogen receptor-positive early breast cancer, but long-term aromatase inhibitor use may cause bone loss and increase fracture risk." | 5.13 | Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. ( Bundred, NJ; Campbell, ID; Coleman, RE; Davidson, N; DeBoer, RH; Eidtmann, H; Miller, JC; Monnier, A; Neven, P; Schenk, NL; von Minckwitz, G, 2008) |
| "17 trial, conducted by the National Cancer Institute of Canada Clinical Trials Group, 5170 breast cancer patients (median age = 62 years; range = 32-94 years) who were disease free after approximately 5 years of adjuvant tamoxifen treatment were randomly assigned to treatment with letrozole (2583 women) or placebo (2587 women)." | 5.13 | Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. ( Chapman, JA; Goss, PE; Ingle, JN; Meng, D; Muss, HB; Palmer, M; Parulekar, W; Shepherd, L; Yu, C, 2008) |
| "With 1 year of follow-up, results of the primary end point of the Zometa-Femara Adjuvant Synergy Trial (Z-FAST) indicate that upfront zoledronic acid therapy prevents bone loss in the LS in postmenopausal women receiving adjuvant letrozole for early-stage breast cancer." | 5.12 | Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. ( Beck, JT; Brufsky, A; Carroll, R; Harker, WG; Hohneker, J; Lacerna, L; Perez, EA; Petrone, S; Seidler, C; Tan-Chiu, E, 2007) |
| "Postmenopausal breast cancer (BC) patients receiving adjuvant aromatase inhibitor therapy are at risk of progressive bone loss and fractures." | 2.77 | Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. ( Argonza-Aviles, E; Beck, JT; Bosserman, L; Brufsky, AM; Ericson, SG; Harker, WG; Hohneker, J; Jin, L; Perez, EA; Seidler, C; Vogel, C; Warsi, G, 2012) |
| "Postmenopausal women with breast cancer (BC) are at increased risk for bone loss." | 2.74 | Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. ( Alberts, S; Dentchev, T; Hines, SL; Johnson, DB; Kahanic, S; Liu, H; Loprinzi, CL; Mazurczak, MA; Mincey, B; Nikcevich, DA; Perez, EA; Schaefer, PL; Sloan, JA, 2009) |
| "Letrozole treatment reduced serum estrone (E1) and estradiol (E2) to near undetectable levels (p < 0." | 2.70 | Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. ( Heshmati, HM; Khosla, S; Melton, LJ; O'Fallon, WM; Riggs, BL; Robins, SP, 2002) |
| "Postmenopausal women with early breast cancer (EBC) are already at risk for bone loss, osteoporosis and fracture as they age because of declining estrogen levels." | 2.46 | Women and bone health: maximizing the benefits of aromatase inhibitor therapy. ( Tang, SC, 2010) |
| "Women undergoing treatment for breast cancer often have a number of pre-existing risk factors for bone loss, including existing or induced postmenopausal status." | 2.43 | Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. ( Aapro, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (61.11) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Decensi, A | 1 |
| Sun, Z | 1 |
| Guerrieri-Gonzaga, A | 1 |
| Thürlimann, B | 1 |
| McIntosh, C | 1 |
| Tondini, C | 1 |
| Monnier, A | 2 |
| Campone, M | 1 |
| Debled, M | 1 |
| Schönenberger, A | 1 |
| Zaman, K | 1 |
| Johansson, H | 1 |
| Price, KN | 1 |
| Gelber, RD | 1 |
| Goldhirsch, A | 1 |
| Coates, AS | 1 |
| Aebi, S | 1 |
| Wagner-Johnston, ND | 1 |
| Sloan, JA | 2 |
| Liu, H | 2 |
| Kearns, AE | 1 |
| Hines, SL | 2 |
| Puttabasavaiah, S | 1 |
| Dakhil, SR | 1 |
| Lafky, JM | 1 |
| Perez, EA | 6 |
| Loprinzi, CL | 2 |
| Brufsky, A | 2 |
| Bundred, N | 1 |
| Coleman, R | 1 |
| Lambert-Falls, R | 1 |
| Mena, R | 1 |
| Hadji, P | 1 |
| Jin, L | 3 |
| Schenk, N | 2 |
| Ericson, S | 1 |
| Mincey, B | 1 |
| Dentchev, T | 1 |
| Johnson, DB | 1 |
| Schaefer, PL | 1 |
| Alberts, S | 1 |
| Kahanic, S | 1 |
| Mazurczak, MA | 1 |
| Nikcevich, DA | 1 |
| Brufsky, AM | 2 |
| Bosserman, LD | 1 |
| Caradonna, RR | 1 |
| Haley, BB | 1 |
| Jones, CM | 1 |
| Moore, HC | 1 |
| Warsi, GM | 1 |
| Ericson, SG | 2 |
| Logman, JFS | 1 |
| Heeg, BMS | 1 |
| Botteman, MF | 1 |
| Kaura, S | 1 |
| van Hout, BA | 1 |
| Tang, SC | 1 |
| Harker, WG | 2 |
| Beck, JT | 2 |
| Bosserman, L | 1 |
| Vogel, C | 1 |
| Seidler, C | 2 |
| Warsi, G | 1 |
| Argonza-Aviles, E | 1 |
| Hohneker, J | 2 |
| Llombart, A | 1 |
| Frassoldati, A | 1 |
| Paija, O | 1 |
| Sleeboom, HP | 1 |
| Jerusalem, G | 1 |
| Mebis, J | 1 |
| Deleu, I | 1 |
| Miller, J | 1 |
| Neven, P | 2 |
| Safra, T | 1 |
| Bernstein-Molho, R | 1 |
| Greenberg, J | 1 |
| Pelles-Avraham, S | 1 |
| Stephansky, I | 1 |
| Sarid, D | 1 |
| Inbar, MJ | 1 |
| Stemmer, SM | 1 |
| Geffen, DB | 1 |
| Aapro, M | 1 |
| Michaud, LB | 1 |
| Higa, GM | 1 |
| Carroll, R | 1 |
| Tan-Chiu, E | 1 |
| Lacerna, L | 1 |
| Petrone, S | 1 |
| Bundred, NJ | 1 |
| Campbell, ID | 1 |
| Davidson, N | 1 |
| DeBoer, RH | 1 |
| Eidtmann, H | 1 |
| von Minckwitz, G | 1 |
| Miller, JC | 1 |
| Schenk, NL | 1 |
| Coleman, RE | 1 |
| Chapman, JA | 1 |
| Meng, D | 1 |
| Shepherd, L | 1 |
| Parulekar, W | 1 |
| Ingle, JN | 1 |
| Muss, HB | 1 |
| Palmer, M | 1 |
| Yu, C | 1 |
| Goss, PE | 1 |
| Panasci, LC | 1 |
| Heshmati, HM | 1 |
| Khosla, S | 1 |
| Robins, SP | 1 |
| O'Fallon, WM | 1 |
| Melton, LJ | 1 |
| Riggs, BL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigating Bone Density and Bone Loss Without Baseline Information[NCT00369850] | Phase 3 | 458 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| A Randomized, Controlled, Open-Label Trial of Empiric Prophylactic vs. Delayed Use of Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women With Breast Cancer Initiating Therapy With Letrozole After Tamoxifen[NCT00107263] | Phase 3 | 558 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Phase 3 Study of the Effect of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving the Aromatase Inhibitor, Letrozole, in the Adjuvant Setting[NCT00376740] | Phase 3 | 90 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Multicenter, Randomized, Phase II Study of Neoadjuvant Chemotherapy Associated or Not With Zoledronate and Atorvastatin in Triple Negative Breast Cancers - YAPPETIZER Study[NCT03358017] | Phase 2 | 54 participants (Actual) | Interventional | 2018-03-05 | Completed | ||
| A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in Triple Negative Breast Cancer Patients, According to p53 Level[NCT02347163] | Phase 2 | 22 participants (Actual) | Interventional | 2015-02-03 | Terminated (stopped due to The study stopped prematurely due to the low accrual rate) | ||
| Aromatase Inhibitors: Skeletal Effects and the Role of CYP19 Gene Polymorphisms[NCT00603967] | 151 participants (Actual) | Interventional | 2006-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for letrozole and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
Topics: Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; | 2006 |
12 trials available for letrozole and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Density; Breast | 2014 |
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Topics: Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Breas | 2015 |
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents | 2008 |
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density; Bone Density Conservation Agent | 2009 |
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents | 2009 |
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone and Bones; Bone Density; Bon | 2012 |
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents | 2012 |
The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase In | 2011 |
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Density; Breast Neoplasms; Collagen Type I; Diphosphonates; | 2007 |
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; | 2008 |
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; | 2008 |
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; | 2008 |
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; | 2008 |
Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.
Topics: Age Factors; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Cardiovascular Disease | 2008 |
Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women.
Topics: Aged; Aromatase Inhibitors; Bone Remodeling; Bone Resorption; Double-Blind Method; Enzyme Inhibitors | 2002 |
4 other studies available for letrozole and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breas | 2010 |
Letrozole in postmenopausal hormone-responsive early-stage breast cancer : a viewpoint by Laura B. Michaud.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy | 2006 |
Letrozole in postmenopausal hormone-responsive early-stage breast cancer: a viewpoint by Gerald M. Higa.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Tria | 2006 |
Aromatase inhibitors: treatment of advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Humans; Letrozo | 2001 |